Study details
Enrolling now
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
Icahn School of Medicine at Mount Sinai
NCT IDNCT04353778ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
55
Study length
about 5.5 years
Ages
18+
Locations
1 site in NY
About this study
Researchers are testing whether a treatment, non-invasive vagal nerve stimulation, or pyridostigmine can help with gastrointestinal problems and inflammation linked to vagus nerve dysfunction in people living with HIV. The trial will explore how the vagus nerve affects inflammation in the gut of people with HIV.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebos
- 2.Take Pyridostigmine
- 3.Undergo non-invasive vagal nerve stimulation
PhasePhase 1/Phase 2
DrugPyridostigmine
Primary goalIL6 measurement [Time Frame: 5 years]
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
pyridostigmine
Endpoints
Primary: IL6 measurement [Time Frame: 5 years]
Procedures
therapy
Body systems
Immune, Infectious